Immunomolecular and reactivity landscapes of gut IgA subclasses in homeostasis and inflammatory bowel disease
The human gut includes plasma cells (PCs) expressing immunoglobulin A1 (IgA1) or IgA2, two structurally distinct IgA subclasses with elusive regulation, function, and reactivity. We show here that intestinal IgA1+ and IgA2+ PCs co-emerged early in life, comparably accumulated somatic mutations, and...
Saved in:
Published in | The Journal of experimental medicine Vol. 221; no. 12 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Rockefeller University Press
02.12.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The human gut includes plasma cells (PCs) expressing immunoglobulin A1 (IgA1) or IgA2, two structurally distinct IgA subclasses with elusive regulation, function, and reactivity. We show here that intestinal IgA1+ and IgA2+ PCs co-emerged early in life, comparably accumulated somatic mutations, and were enriched within short-lived CD19+ and long-lived CD19− PC subsets, respectively. IgA2+ PCs were extensively clonally related to IgA1+ PCs and a subset of them presumably emerged from IgA1+ precursors. Of note, secretory IgA1 (SIgA1) and SIgA2 dually coated a large fraction of mucus-embedded bacteria, including Akkermansia muciniphila. Disruption of homeostasis by inflammatory bowel disease (IBD) was associated with an increase in actively proliferating IgA1+ plasmablasts, a depletion in long-lived IgA2+ PCs, and increased SIgA1+SIgA2+ gut microbiota. Such increase featured enhanced IgA1 reactivity to pathobionts, including Escherichia coli, combined with depletion of beneficial A. muciniphila. Thus, gut IgA1 and IgA2 emerge from clonally related PCs and show unique changes in both frequency and reactivity in IBD. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Disclosures: L. Comerma reported personal fees from Roche, MSD, AstraZeneca, and Diaceutics and non-financial support from Roche, MSD, AstraZeneca, and Phillips outside the submitted work. M. Iglesias reported personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, Roche, Astellas, Merck, Agilent, and Seagen outside the submitted work. No other disclosures were reported. R. Mehr, A. Cerutti, and G. Magri contributed equally to this paper. G. Magri’s current affiliation is Immunology Unit, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain. M. Uzzan’s current affiliation is Department of gastroenterology, Hospital Henri Mondor, APHP, Creteil France; INSERM U955, IMRB, Creteil, France. E.K. Grasset’s current affiliation is Department of Pediatrics, Gale and Ira Drukier Institute for Children's Health, Weill Cornell Medicine, New York, NY, USA. S. Tejedor Vaquero and H. Neuman contributed equally to this paper. |
ISSN: | 0022-1007 1540-9538 1540-9538 |
DOI: | 10.1084/jem.20230079 |